Ozlo Raises $22M Series B to Expand Sleep Technology

A side sleeper gives Ozlo very little room for error. The device has to fit between an ear and a pillow, stay useful through the night and earn another place in tomorrow's routine. That physical relationship helps explain why the Boston sleep technology company is drawing capital for a business that reaches beyond selling earbuds.

Ozlo announced a $22M Series B led by Modi Ventures on October 29, 2026. The announced total includes previously issued convertible instruments. The company plans to expand Sleepbuds globally, deepen its hardware and software work, and advance regulatory preparation for a tinnitus product it intends to submit to the FDA for review.

Co-founders N.B. Patil, Brian Mulcahey and Charles Taylor bring the continuity of a product they helped develop at Bose. Their opportunity now extends into the relationship among a consumer device, sleep content and clinical care, with each part asking something different of the customer and the company.

What Ozlo's Series B finances

The financing backs an existing consumer product alongside a broader development program. Ozlo says it has exceeded 260,000 customers in under 2 years, an issuer-reported measure of reach that offers no direct view of revenue, repeat use or profitability. Its expansion plan includes engineering, research, new products, partnerships and greater awareness among consumers and clinicians.

Modi Ventures led the round. Returning participants include LifeArc, Artis Ventures, Resmed, Scrum Ventures, Drive by DraftKings, Wheelhouse 360, WISE Ventures, Niremia Collective, Accelerate Ventures and World Solver Syndicate. Ozlo also names Nick Foles, Danny Davis, Melissa Urban and Michael Gervais as participants, bringing sports, consumer wellness and performance backgrounds into the financing group.

The capital history deserves careful handling because the latest headline includes instruments issued earlier. LifeArc's 2023 annual review confirms that LifeArc Ventures and ARTIS Ventures co-led a $10M Series A. The current announcement gives no allocation between new cash and converted instruments, and supplies no valuation or reconciled lifetime funding total. Those omissions make adding historical headlines together an unreliable way to describe the company's resources.

For the investor group, the assignment is unusually tangible: help a small piece of hardware become dependable enough to support a larger business around it. Global expansion also extends the company's responsibility to people who expect the product to work when they are least interested in troubleshooting electronics.

The product decision that travels into bed

Sleepbuds 2 uses noise masking, with consistent sound and a passive seal intended to reduce the impact of interruptions such as snoring and street noise. Ozlo describes a small, low-profile shape designed for side sleeping. The product's commercial appeal depends on how those choices behave together through an ordinary night, rather than how impressive any feature appears in isolation.

Ozlo markets up to 14 hours of battery life, subject to volume, audio, features and other operating conditions. Its current product experience includes streaming audio, built-in sounds, a private alarm and sleep-pattern and environmental insights. These are the company's descriptions of product functions; the funding announcement supplies no independent evaluation of diagnostic accuracy or treatment outcomes.

The founders' history gives this design work a particular weight. In N.B. Patil's account of the company's origins, Patil, Mulcahey and Taylor helped develop the original Bose Sleepbuds, then acquired and licensed key sleep-related technology after Bose discontinued the product. Continuing that work meant inheriting a customer need that survived the earlier business decision.

Patil is identified as CEO in the new announcement. The founders' accumulated audio experience matters because a sleep product has to balance comfort, sound and power while asking very little of its wearer. A customer can admire the engineering in the afternoon and remove the device at midnight; the company has to design for both moments.

Content and care create different relationships

Ozlo's Calm collaboration, announced in November 2025, brought the sleep audio hardware together with Calm's relaxation and sleep content. The arrangement gives Ozlo a way to make the experience around the device more useful without producing every piece of content itself. It also brings a familiar wellness brand into a purchase whose value is realized through repeated use.

The new financing announcement describes another relationship with Dreem Health, intended to connect people using Ozlo's technology with sleep specialists who can evaluate, diagnose and treat common sleep disorders. Dreem Health operates a virtual sleep clinic with licensed providers. The partnership's proposed path into care gives the hardware company a role in helping people reach another professional relationship.

That division of work matters commercially and clinically. A person buying help with nighttime noise may eventually need an evaluation that a retail product cannot provide. A content partner can enrich the bedtime routine; a clinician has to assess the individual. Building those connections gives Ozlo more ways to remain useful while keeping the responsibilities legible.

For other companies building health-adjacent consumer hardware, the relevant observation is how much of the experience can sit outside the device maker. Ozlo's expanding relationships could make its product a more durable part of the night. The company still has to ensure that each added service feels like help to somebody who came to bed hoping for fewer things to manage.

Tinnitus brings a separate evidence burden

Ozlo says part of the financing will support regulatory work toward submitting a tinnitus product to the FDA. That describes a development and submission plan, with no clearance or approval established by this announcement. The business is moving toward a more specific clinical claim while continuing to sell a consumer sleep product with its own uses and limitations.

The National Institute on Deafness and Other Communication Disorders describes tinnitus as the perception of sound without an external source and discusses sound-based and behavioral approaches to management. That context explains why audio technology belongs in the conversation. It supplies no product-specific validation for Ozlo, whose planned tinnitus offering requires its own evidence and regulatory work.

This creates a different development calendar from a consumer feature release. Comfort and a workable nightly routine may help a person tolerate a device, but clinical evaluation asks further questions about the proposed use and the results it can support. Ozlo has identified regulatory preparation as a use of funds without disclosing a submission date, detailed study results or a commercialization timetable for that product.

The founders are therefore extending a familiar piece of hardware into relationships that demand different kinds of trust. A customer expects quiet, a content partner expects a coherent experience, and a clinical pathway depends on appropriate evaluation. As those relationships develop, the Sleepbuds wearer still begins with the simplest decision in the system: whether the device is comfortable enough to keep wearing tonight.